Prognostic significance of telomeraseassociated parameters in glioblastoma: Effect of patient age

Neuro-Oncology

Volumn 15, Issue 4, 2013, Pages 423-432

  Lötsch, Daniela ^a,b   Ghanim, Bahil ^a,b   Laaber, Magdalena ^c   Wurm, Gabriele ^d   Weis, Serge ^c   Lenz, Stefan ^c   Webersinke, Gerald ^c   Pichler, Josef ^c   Berger, Walter ^a,b   Spiegl Kreinecker, Sabine ^c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c KEPLER UNIVERSITY HOSPITAL   (Austria)

^d Krankenhaus der Barmherzigen Schwestern Wien Betriebsgesellschaft   (Austria)

Author keywords

Age; Glioblastoma; Prognosis; Survival; Telomerase

Indexed keywords

ISOCITRATE DEHYDROGENASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TELOMERASE; DNA METHYLTRANSFERASE; IDH1 PROTEIN, HUMAN; MESSENGER RNA; MGMT PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TERT PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER SURVIVAL; FEMALE; GENE MUTATION; GENE SEQUENCE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; AGE; BRAIN TUMOR; CANCER STAGING; CLINICAL TRIAL; DNA METHYLATION; ENZYMOLOGY; FOLLOW UP; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; MUTATION; PROGNOSIS; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL RATE; TELOMERE; VERY ELDERLY;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROGNOSIS; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TELOMERASE; TELOMERE; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84875726959     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nos329     Document Type: Article

References (46)

1. Blackburn EH. Structure and function of telomeres. Nature. 1991;350(6319):569-573.
2. Greider CW. Telomere length regulation. Annu Rev Biochem. 1996;65:337-365.
3. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer. 1997;33(5):787-791.
4. Soria JC, Vielh P, el-Naggar AK. Telomerase activity in cancer: a magic bullet or a mirage? Adv Anat Pathol. 1998;5(2):86-94.
5. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459-466.
6. Ducray F, El Hallani S, Idbaih A. Diagnostic and prognostic markers in gliomas. Curr Opin Oncol. 2009;21(6):537-542.
7. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352(10):997-1003.
8. Spiegl-Kreinecker S, Pirker C, Filipits M, et al. O6-methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients. Neuro Oncol. 2010;12(1):28-36.
9. Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol. 2009;27(34):5743-5750.
10. Langford LA, Piatyszek MA, Xu R, Schold SC Jr., Shay JW. Telomerase activity in human brain tumours. Lancet. 1995;346(8985):1267-1268.
11. Maes L, Van Neste L, Van Damme K, et al. Relation between telomerase activity, hTERT and telomere length for intracranial tumours. Oncol Rep. 2007;18(6):1571-1576.
12. Shervington A, Patel R. Differential hTERT mRNA processing between young and older glioma patients. FEBS Lett. 2008;582(12):1707-1710.
13. Shervington A, Patel R, Lu C, et al. Telomerase subunits expression variation between biopsy samples and cell lines derived from malignant glioma. Brain Res. 2007;1134(1):45-52.
14. Boldrini L, Pistolesi S, Gisfredi S, et al. Telomerase activity and hTERT mRNA expression in glial tumors. Int J Oncol. 2006;28(6):1555-1560.
15. Hakin-Smith V, Jellinek DA, Levy D, et al. Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet. 2003;361(9360):836-838.
16. Berger W, Elbling L, Micksche M. Expression of the major vault protein LRP in human non-small-cell lung cancer cells: activation by short-term exposure to antineoplastic drugs. Int J Cancer. 2000;88(2):293-300.
17. O'Callaghan N, Dhillon V, Thomas P, Fenech M. A quantitative realtime PCR method for absolute telomere length. BioTechniques. 2008;44(6):807-809.
18. Callicott RJ, Womack JE. Real-time PCR assay for measurement of mouse telomeres. Comp Med. 2006;56(1):17-22.
19. Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids Res. 2002;30(10):e47.
20. Gan Y, Mo Y, Johnston J, Lu J, Wientjes MG, Au JL. Telomere maintenance in telomerase-positive human ovarian SKOV-3 cells cannot be retarded by complete inhibition of telomerase. FEBS Lett. 2002; 527(1-3):10-14.
21. Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009;118(4):469-474.
22. Brandes AA, Tosoni A, Cavallo G, et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from Gruppo Italiano Cooperativo di Neuro-oncologia (GICNO). Br J Cancer. 2006;95(9):1155-1160.
23. Hegi ME, Diserens AC, Godard S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res. 2004;10(6):1871-1874.
24. Karayan-Tapon L, Quillien V, Guilhot J, et al. Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. J Neurooncol. 2009;97(3):311-322.
25. Royds JA, Al Nadaf S, Wiles AK, et al. The CDKN2A G500 allele is more frequent in GBM patients with no defined telomere maintenance mechanism tumors and is associated with poorer survival. PLoS One. 2011;6(10):e26737.
26. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266(5193):2011-2015.
27. Shay JW, Wright WE. Telomerase therapeutics for cancer: challenges and new directions. Nat Rev Drug Discov. 2006;5(7):577-584.
28. Chong EY, Lam PY, Poon WS, Ng HK. Telomerase expression in gliomas including the nonastrocytic tumors. Hum Pathol. 1998;29(6):599-603.
29. Hiraga S, Ohnishi T, Izumoto S, et al. Telomerase activity and alterations in telomere length in human brain tumors. Cancer Res. 1998;58(10):2117-2125.
30. Le S, Zhu JJ, Anthony DC, Greider CW, Black PM. Telomerase activity in human gliomas. Neurosurgery. 1998;42(5):1120-1124.
31. Morii K, Tanaka R, Onda K, Tsumanuma I, Yoshimura J. Expression of telomerase RNA, telomerase activity, and telomere length in human gliomas. Biochem Biophys Res Commun. 1997;239(3): 830-834.
32. Sano T, Asai A, Mishima K, Fujimaki T, Kirino T. Telomerase activity in 144 brain tumours. Br J Cancer. 1998;77(10):1633-1637.
33. Valls C, Pinol C, Rene JM, Buenestado J, Vinas J. Telomere length is a prognostic factor for overall survival in colorectal cancer. Colorectal Dis. 2011;13(11):1265-1272.
34. Heaphy CM, Subhawong AP, Hong SM, et al. Prevalence of the alternative lengthening of telomeres: telomere maintenance mechanism in human cancer subtypes. Am J Pathol. 2011;179(4): 1608-1615.
35. McDonald KL, McDonnell J, Muntoni A, et al. Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival. J Neuropathol Exp Neurol. 2010;69(7):729-736.
36. Nakatani K, Yoshimi N, Mori H, et al. The significant role of telomerase activity in human brain tumors. Cancer. 1997;80(3):471-476.
37. Persson A, Englund E. Different assessments of immunohistochemically stained Ki-67 and hTERT in glioblastoma multiforme yield variable results: a study with reference to survival prognosis. Clin Neuropathol. 2008;27(4):224-233.
38. Alonso MM, Fueyo J, Shay JW, et al. Expression of transcription factor E2F1 and telomerase in glioblastomas: mechanistic linkage and prognostic significance. J Natl Cancer Inst. 2005;97(21):1589-1600.
39. Fukushima T, Yoshino A, Katayama Y, Watanabe T, Kusama K, Moro I. Prediction of clinical course of diffusely infiltrating astrocytomas from telomerase expression and quantitated activity level. Cancer Lett. 2002;187(1-2):191-198.
40. Henson JD, Hannay JA, McCarthy SW, et al. A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res. 2005;11(1):217-225.
41. Blackburn EH, Greider CW, Szostak JW. Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging. Nat Med. 2006;12(10):1133-1138.
42. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer. 2010;17(1):98-110.
43. Falchetti ML, Mongiardi MP, Fiorenzo P, et al. Inhibition of telomerase in the endothelial cells disrupts tumor angiogenesis in glioblastoma xenografts. Int J Cancer. 2008;122(6):1236-1242.
44. Falchetti ML, Pierconti F, Casalbore P, et al. Glioblastoma induces vascular endothelial cells to express telomerase in vitro. Cancer Res. 2003;63(13):3750-4.
45. Gorbunova V, Seluanov A. Telomerase as a growth-promoting factor. Cell Cycle. 2003;2(6):534-537.
46. Silvestre DC, Pineda JR, Hoffschir F, et al. Alternative lengthening of telomeres in human glioma stem cells. Stem Cells. 2011;29(3):440-451.